论文部分内容阅读
目的:探讨孟鲁司特钠联合盐酸氨溴索对肺炎支原体肺炎患儿免疫功能和炎性因子的影响。方法:选择2018年1-12月台州市肿瘤医院收治的肺炎支原体肺炎患儿146例，依据随机数字表法分为观察组与对照组，每组73例。两组患儿入院后均采取常规治疗，包括持续低流量吸氧、镇静、营养支持、平喘、祛痰、维持酸碱平衡、纠正水电解质紊乱及抗感染治疗等。对照组给予盐酸氨溴索，观察组给予孟鲁司特钠联合盐酸氨溴索。两组疗程均为2周。比较两组主要症状消失时间，治疗前后肺功能、免疫功能和炎性因子变化及治疗疗效。结果:观察组咳嗽消失时间[(3.65±0.87)d]、咳痰消失时间[(3.49±0.46)d]和退热时间[(3.32±0.61)d]均短于对照组[(5.54±0.91)d、(5.32±0.71)d和(4.65±0.79)d](n t＝12.827、18.482、11.385，均n P<0.05)。观察组治疗后用力呼气量与用力肺活量比值(FEVn 1/FVC)[(84.36±6.78)%]、最大呼气第1秒容积(FEVn 1)[(2.87±0.54)L]和每分钟最大通气量(MVV)[(89.74±4.31)L/min]均高于对照组[(70.18±7.54)%、(2.05±0.41)L和(82.13±3.78)L/min](n t＝11.948、10.333、11.342，均n P<0.05)。观察组治疗后血清免疫球蛋白(Ig)A[(0.89±0.14)pg/L]、IgG[(9.01±0.65)pg/L]和IgM[(1.48±0.21)pg/L]均低于对照组[(1.06±0.12)pg/L、(9.81±0.54)pg/L和(1.81±0.15)pg/L](n t＝7.887、8.089、10.925，均n P<0.05)。观察组治疗后血清肿瘤坏死因子α(TNF-α)[(24.13±6.59)mg/L]、白细胞介素6(IL-6)[(16.32±5.21)ng/L]和C反应蛋白(CRP)[(7.28±1.43)mg/L]均低于对照组[(37.48±8.97)mg/L、(28.78±6.19)ng/L和(18.93±3.45)mg/L](均n P<0.05)。观察组总有效率(91.78%)高于对照组(73.34%)(χn 2＝7.180，n P<0.05)。n 结论:孟鲁司特钠联合盐酸氨溴索对肺炎支原体肺炎患儿疗效明显，患儿免疫功能明显改善，炎性反应明显减轻。“,”Objective:To investigate the effect of montelukast sodium tablets combined with ambroxol hydrochloride on immune function and inflammatory factors in children with Mycoplasma pneumoniae pneumonia.Methods:From January 2018 to December 2018, 146 children with Mycoplasma pneumoniae pneumonia admitted in Taizhou Tumor Hospital were randomly divided intoobservation group and control group according the random digital table method, with 73 cases in each group.Both two groups were treated with routine treatment after admission, including continuous low flow oxygen inhalation, sedation, nutritional support, antiasthmatic, expectorant, maintenance of acid-base balance, correction of water electrolyte disorder and anti-infection treatment.The control group was treated with ambroxol hydrochloride, while the observation group was treated with montelukast sodium tablets combined with ambroxol hydrochloride.The course of treatment in both two groups was 2 weeks.The disappearance time of main symptoms, changes of lung function, immune function and inflammatory factors before and after treatment were compared between the two groups.Results:The disappearance time of cough [(3.65±0.87)d], expectoration[(3.49±0.46)d] and fever[(3.32±0.61)d] in the observation group were shorter than those in the control group [(5.54±0.91)d, (5.32±0.71)d and (4.65±0.79)d] (n t=12.827, 18.482, 11.385, all n P<0.05). The FEVn 1/FVC [(84.36±6.78)%], FEVn 1[(2.87±0.54)L] and MVV[(89.74±4.31)L/min] in the observation group were higher than those in the control group[(70.18±7.54)%, (2.05±0.41)L and (82.13±3.78)L/min] (n t=11.948, 10.333, 11.342, all n P<0.05). The serum IgA[(0.89±0.14)pg/L], and the IgG[(9.01±0.65)pg/L] and IgM [(1.48±0.21)pg/L] in the observation group were lower than those in the control group [(1.06±0.12)pg/L, (9.81±0.54)pg/L and (1.81±0.15)pg/L] (n t=7.887, 8.089 and 10.925, all n P<0.05). The serum levels of TNF-α [(24.13±6.59)mg/L], IL-6[(16.32±5.21)ng/L] and CRP[(7.28±1.43)mg/L] in the observation group were lower than those in the control group[(37.48±8.97)mg/L, (28.78±6.19)ng/L and (18.93±3.45)mg/L](alln P<0.05). The total effective rate of the observation group(91.78%) was higher than that of the control group(73.34%)(χn 2=7.180, n P<0.05).n Conclusion:Montelukast sodium tablet combined with ambroxol hydrochloride has obvious curative effect on children with Mycoplasma pneumoniae pneumonia, and the immune function and inflammatory reaction of children are obviously improved.